Introduction
============

In 2018, approximately 1,735,350 new cancer cases and 609,640 cancer deaths were reported in the United States [@B1]. Despite tremendous efforts to reduce deaths due to cancer, Cancer has been most deadly diseases worldwide. It is thus required for identify more effective biomarkers for cancer prognosis.

Long non-coding RNAs (lncRNAs) have no or little protein-coding potential with more than 200 nt in length [@B2]. Compared to protein-coding genes, lncRNAs exhibit typically higher degree of spatio-temporal specificity [@B3]. Collecting evidences suggests that lncRNAs are aberrant expressed in multiple human malignancies and has critical roles in regulating a variety of cellular processes, including cell apoptosis, proliferation and,invasion [@B4]-[@B6]. Moreover, several lncRNAs has been identified as sensitive prognostic biomarkers for cancers, such as TSLNC8 for hepatocellular carcinoma and HOTAIR for glioblastoma multiforme [@B7], [@B8]. Zinc finger E-box binding homeobox 1 antisense 1 (ZEB1-AS1) is a noncoding antisense RNA located on chromosome 10 which is in the opposite direction of ZEB1 gene transcription. A number of studies have reported the oncogenic function of ZEB1-AS1 mainly to be mediated through its gene silencing activity of ZEB1. In hepatocellular carcinoma, higher ZEB1-AS1expression is known to be more associated metastasis through ZEB1 expression and poor patient survival [@B9]. It has also been shown recently that ZEB1-AS1 plays a role in the proliferation and migration of osteosarcoma cells [@B10]. Moreover, increasing evidence has shown that ZEB1-AS1 is dysregulated in a variety of human cancers, and this dysfunctional expression is associated with the survival and clinicopathologic characteristics in cancer patients. However, due to small sample size and/or methodological limitations, the prognostic significance of ZEB1-AS1 expression in cancer remains to be elucidated. Therefore, it is essential to highlight the important role of ZEB1-AS1 in cancer base on larger samples.

In the present study, we carried out a meta-analysis of all relevant publications to exploit the prognostic effect of ZEB1-AS1 in cancer. Levels of ZEB1-AS1 were closely correlated with increased likelihood of tumor differentiation, depth of invasion, lymph node metastasis, distant metastasis, and tumor stage but not tumor size in cancer. Furthermore, Overall results confirm a correlation between increased ZEB1-AS1 expression and poor overall survival (OS).

Materials and Methods
=====================

Search strategy
---------------

A literature search was performed in the electronic databases of PubMed and Embase. The latest search was applied on June 13, 2018. Literature search terms were included ("ZEB1-AS1" OR \"lncRNA ZEB1-AS1\") AND (tumor OR cancer OR neoplasm OR carcinoma). Only English language publications were included in this study.

Study selection criteria
------------------------

The following criteria for study eligibility were set before collecting articles: (1) associations of ZEB1-AS1 expression levels with clinicopathological features or survival in multiple human tumors were described; or (2) patients were grouped into two groups based on high and low expression levels of ZEB1-AS1 in human tumor tissue. (3) expression levels of ZEB1-AS1 in the patients were measured by qRT-PCR.

The following criteria were used to exclude studies from this meta-analysis: (1) reviews, letters, expert opinions, case reports, commentaries and editorials; (2) studies without original data; (3) duplicate articles; (4) sample cases fewer than 30; (5) non-human studies.

Data extraction and methodological assessment
---------------------------------------------

Two researchers independently evaluated study eligibility. Disagreements were resolved by with a third researcher. The following data were retrieved: first author\'s surname, publication year, country of origin, tumor type, sample size, ZEB1-AS1 expression detection method, cut-off value, outcome measures, hazard ratio (HR) and its corresponding 95% confident interval (CI), the number of patients with lager tumor size, depth of tumor invasion, histological differentiation, lymph node metastasis, distant metastasis and tumor stage.

Statistical methods
-------------------

Pooled odds ratios (ORs) or hazard ratios (HRs) with 95 % confidence intervals (CIs) were calculated to determine ZEB1-AS1 as a prognostic biomarker in human cancer. The heterogeneity across the included studies was measured by the Chi squared (χ2)-based Q test [@B11]. *P* \< 0.1 for the Q test (*P*h) and*I*^2^ \> 50% indicated existence of significant heterogeneity among studies. The fixed effects model was used to analyze the pooled results when the included studies showed heterogeneity [@B12]. Otherwise, the random effects model was used [@B13]. Also, the potential publication bias was assessed by the Begg\'s funnel plot [@B14]. For the eligible studies that provided both the univariate and multivariate test, the multivariate values were preferred as the multivariate values had higher precision on interpreting covariates. When studies only report Kaplan-Meier curves, the Enguage Digitizer tool (Version 4.1) was used to digitize the survival data from the reported curves. All the *P*-values were determined by a 2-tailed t test and *P*\<0.05 was representative of a statistically significance. The STATA version 12.0 software (Stata Corporation, College Station, TX) was used to perform all statistical analyses.

Results
=======

Characteristics of the included studies
---------------------------------------

As shown in Figure [1](#F1){ref-type="fig"}, a total of fourteen articles were included in the current meta-analysis [@B9], [@B15]-[@B27]. Additionally, Table [1](#T1){ref-type="table"} summarized the main characteristics of the fourteen studies included in the present meta-analysis. All fourteen studies were conducted in from China, and addressed nine different tumor types: three focused on colorectal cancer, three focused on gastric cancer, one focused on osteosarcoma, one focused on hepatocellular carcinoma, one focused on bladder cancer, one focused on prostate cancer, two focused on glioma, one focused on leukemia and one focused on esophageal squamous cell carcinoma (ESCC). In these included literatures, the level of ZEB1-AS1 was detected in patient\'s tumor tissue by RT-PCR; and the negative control was adjacent normal tissue. The reference gene of ZEB1-AS1 in these studies was found to be inconsistent, including GAPDH and *β*-actin.

Association of ZEB1-AS1 expression with tumor size
--------------------------------------------------

As shown in Figure [2](#F2){ref-type="fig"}, ten studies examined the association between ZEB1-AS1 and tumor size in six types of cancer. Significant heterogeneity was found among the studies (*I²*=56.5%, *P~Q~* =0.014) and then the random-effects model was applied. No significant connection was found between a high ZEB1-AS1 expression level and high tumor size in cancer patients (OR=1.25, 95%CI 0.79-1.96, *P*=0.339) (Figure [2](#F2){ref-type="fig"}).

Association of ZEB1-AS1 expression with depth of invasion
---------------------------------------------------------

Six studies explored the association between ZEB1-AS1 expression levels with depth of invasion. The random-effects model was used for the significant heterogeneity (*I*^2^=76.5%, *P~Q~* =0.001). AS presented in Figure [3](#F3){ref-type="fig"}, the results indicated that the expression of ZEB1-AS1 in cancer was associated with depth of invasion (OR=2.92, 95% CI: 1.22-7.02, *P*=0.016).

Association of ZEB1-AS1 expression with tumor differentiation
-------------------------------------------------------------

There were seven studies reported the association between ZEB1-AS1 expression levels and tumor difference. The fixed-effects model was adopted due to no significant heterogeneity among the studies (*I*^2^=0%, *P~Q~* = 0.82). The results of the forest plot demonstrated that patients with higher expression of ZEB1-AS1 in the tumor tissues may have increased probability of poor differentiation (OR = 2.72; 95% CI: 1.92-3.86,*P* = 0.000) (Figure [4](#F4){ref-type="fig"}).

Association of ZEB1-AS1 expression with lymph node metastasis
-------------------------------------------------------------

Seven studies examined the correlation of ZEB1-AS1 expression with lymph node metastasis in cancer. There was no heterogeneity among the studies (*I*^2^=0%, *P~Q~* = 0.933), and the fixed effects model was adopted. We observed significant association between ZEB1-AS1 expression and lymph node metastasis (OR=3.93, 95%CI: 2.65-5.84, *P*=0.00) (Figure [5](#F5){ref-type="fig"}).

Association of ZEB1-AS1 expression with distant metastasis
----------------------------------------------------------

Four studies examined the association between metastasis and ZEB1-AS1 in different cancers, including colorectal cancer, gastric cancer and osteosarcoma. We found high ZEB1-AS1 expression group had a significant elevated distant metastasis incidence compared with low expression group (OR=5.34, 95%CI: 2.85-10.02, *P*=0.00). There was no heterogeneity among the studies (*I*^2^=0%, *P~Q~* =0.595) (Figure [6](#F6){ref-type="fig"}).

Association of ZEB1-AS1 expression with tumor stage
---------------------------------------------------

As presented in Figure [7](#F7){ref-type="fig"}, nine studies declared the association between the ZEB1-AS1 expression levels and tumor stage in cancer. There was significant heterogeneity in these studies, and the random-effects model was used (*I*^2^ =64.3%, *P~Q~* = 0.004). As a result, patients with a higher expression of ZEB1-AS1 were more liable to developing more advanced tumor stage. (OR=2.46, 95%CI 1.42-4.24,*P*=0.001)

Association between ZEB1-AS1 expression with survival
-----------------------------------------------------

The prognostic value of ZEB1-AS1 in OS was assessed for ten studies with 812 patients. ZEB1-AS1 was significantly associated with OS (pooled HR: 1.94, 95% CI: 1.66-2.22, *P*=0.00) (Figure [8](#F8){ref-type="fig"}). There was no significant heterogeneity across the studies (*I*^2^=0% ,*P~Q~*=0.947). This result manifested that a higher expression of ZEB1-AS1 might be correlated with a poorer OS in cancer patients, which demonstrated that ZEB1-AS1 was an independent factor for survival among patients with cancer.

Publication bias
----------------

Begg\'s funnel plot was conducted to access the publication bias in the studies included in this meta-analysis. Figure [9](#F9){ref-type="fig"} showed no publication bias for tumor size (*P*= 0.939) (Figure [9](#F9){ref-type="fig"}A), depth of invasion (*P*=0.306) (Figure [9](#F9){ref-type="fig"}B), differentiation (*P*= 0.274) (Figure [9](#F9){ref-type="fig"}C), lymph node metastasis (*P*=0.209) (Figure [9](#F9){ref-type="fig"}D), metastasis (*P*=0.114) (Figure [9](#F9){ref-type="fig"}E), TNM stage (*P*= 0.778) (Figure [9](#F9){ref-type="fig"}F), and OS (*P*= 0.183) (Figure [9](#F9){ref-type="fig"}G).

Discussion
==========

Recent years, many studies have indicated that lncRNAs play important roles in gene expression and are widely involved in tumor progression and metastasis [@B28], [@B29]. It suggested these molecules could improve prognostic value by providing precise and valuable information about tumor phenotypes. ZEB1-AS1 is a novel noncoding antisense transcript in the opposite direction of ZEB1 gene, located on chromosome 10 with approximately 2535 nucleotides in length [@B21]. In the recent studies, the expression levels of ZEB1-AS1 are found to be abnormal in different types of tumors. Furthermore, it was a key mediator in cancer progression by promoting invasion and metastasis, including colorectal carcinoma, hepatocellular carcinoma, gastric cancer, prostate cancer, osteosarcoma, ESCC and leukemia [@B30]. Thus, this meta-analysis was performed to evaluate the association between ZEB1-AS1 expression with clinicopathological characteristics and survival in various cancers.

A total of fourteen eligible studies, addressing nine common cancer types, met the selection requirements for inclusion. The meta-analysis results indicated that high ZEB1-AS1 expression is significantly correlated with poor prognosis in patients with different types of cancers. The meta-analysis for the association between increased ZEB1-AS1 expression and clinicopathological parameters was also analyzed in this study, and our results showed that increased ZEB1-AS1 expression was significantly associated with depth of invasion, tumor differentiation, lymph node metastasis, distal metastasis and advanced clinical stage, which may suggest that increased ZEB1-AS1 may be associated with advanced features of cancer. Nevertheless, increased ZEB1-AS1 expression was not found to be associated with tumor size. Notably, the pooled HRs results demonstrated that elevated ZEB1-AS1 expression was positively associated with a shorter OS time. Collectively, these observations provide evidence that ZEB1-AS1 may serve as a potential independent predictive biomarker in cancer patients.

The molecular mechanisms underlying the association between ZEB1-AS1 altered expression and poor clinical outcome in cancer largely unknown. Several articles have suggested ZEB1-AS1 may contribute to migration and invasion of tumors through both positive and negative regulation of gene activity. It is a long known fact that upstream antisense transcription involved in transcriptional regulation of corresponding gene expression [@B31]. Since ZEB1-AS1 is an antisense transcript in the opposite direction of ZEB1 gene, the target gene expression of ZEB1-AS1 focus on ZEB1 which is a crucial modulator of epithelial-mesenchymal transition (EMT) program. For instance, it was first demonstrated that ZEB1-AS1 has a significantly increased the promoter activity of ZEB1 in hepatocellular carcinoma and gastric cancer [@B17], [@B32]. In osteosarcoma, Liu then reported that ZEB1-AS1 could recruit p300 to the ZEB1 promoter region and activate ZEB1 transcription [@B10]. In addition, Lv showed ZEB1-AS1 promoted invasion by inducing the ZEB1-EMT and regulated the proliferation through cyclin D /CDK2 in glioma [@B20]. Another underlying mechanism of lncRNAs as oncogenes is to sponge the tumor-suppressive microRNAs. Study from Su et al. showed that ZEB1-AS1 indirectly inhibited the tumor suppressor miR200c, and further regulated the expression of BMI1, the degradation of which was mediated by directly binding of miR200c [@B21]. In accordance with this finding is another report that the interplay between ZEB1-AS1 and miR-200s contributes to osteosarcoma cell proliferation and migration [@B33]. Moreover, ZEB1-AS1 was found to promote colorectal cancer cells proliferation and invasion via miR-101/ZEB1 axis [@B34]. Increasing evidences also showed that ZEB1-AS1 had functional roles on the activation of signaling pathway, such as ZEB1-AS1 IL-11/STAT3 pathway [@B22]. These evidences indicate that targeting ZEB1-AS1 may affects tumor progression and metastasis and might serve as a novel biomarker for the treatment and prognosis of cancer. Consistent with these mechanisms, we showed in this study that ZEB1-AS1 expression was significantly associated with depth of invasion, tumor differentiation, lymph node metastasis, distal metastasis, advanced clinical stage and a shorter OS. In contrast, increased ZEB1-AS1 expression was not correlated with tumor size. This discrepancy may arise from the heterogeneous molecular profiles embedded in the different types of cancers. Another reason may be that ZEB-AS1 contributes to cancer metastasis but not proliferation in some type of cancer [@B9]. Therefore, the role of ZEB1-AS1 in other non-studied types of cancer and the detailed mechanisms may be further investigated to confirm the role of ZEB1-AS1.

Some limitations still exist in our meta-analysis worth mentioning. First, the number of research, the type of cancers and the total sample size included was relatively small. Second, some HRs and their corresponding 95%CIs were calculated from survival curves, and may be less reliable than those directly obtained from studies. Third, publication bias may exist, despite the fact that no significant publication bias was observed based on funnel plot analysis. Finally, the cut-off values definition for high ZEB1-AS1 expression and the reference gene was not consistent among the included. Therefore, additional large-size, higher quality and multi-center studies with unified criteria for determining ZEB1-AS1 expression are necessary to validate the results in this study.

Taken together, the results of our meta-analysis indicate that the role ZEB-AS1 in prognosis of patients with different types of cancer. However, multi-center, well designed, larger-sample size, and higher-quality studies may be required to further solidify the clinical value of ZEB1-AS1 as prognostic cancer marker.
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###### 

Characteristics of studies in this meta-analysis

                                              ZEB1-AS1 expression                                                                                                          
  ------- ------ ------- -------------- ----- --------------------- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ----------- -------- ---------------- ---------------------
  Fu      2017   China   CRC            108   54                    38   \_   47   \_   24   22   54   23   \_   36        8    11   GAPDH       2.58     Data in paper    2.026(1.493-2.748)
  Gong    2017   China   CRC            63    31                    6    25   14   24   \_   20   32   9    16   8    13   \_   24   GAPDH       median   Survival curve   1.77(1.08-2.91)
  Li      2016   China   HCC            102   51                    23   \_   39   \_   \_   13   51   20        27        \_   11   *β*-actin   median   Survival curve   1.6(1.09-2.36)
  Li      2017   China   GC             124   62                    \_   24   \_   46   10   49   62   \_   25   \_   20   0    22   GAPDH       median   Data in paper    2.363 (1.410-3.962)
  Lin     2017   China   BC             55    37                    23   15   \_   2    \_        18   11   2    \_   0    \_        NM          NM       NM               NM
  Liu     2016   China   osteosarcoma   50    25                    12   \_   \_        6    8    25   5    \_   \_   \_   1    1    GAPDH       median   NM               NM
  Lv      2016   China   Glioma         82    29                    \_   \_   \_   \_   \_   21   53   \_   \_        \_   \_   24   GAPDH       NM       Data in paper    1.885(1.068-3.326)
  Su      2017   China   PC             114   57                    \_   \_   \_   \_   \_   54   57   \_   \_   \_   \_   \_   33   GAPDH       NM       NM               NM
  Wang    2017   China   BL             30    \_                    \_   \_   \_   \_   \_   \_   \_   \_   \_   \_   \_   \_   \_   GAPDH       median   Survival curve   2.14(1.04-4.38)
  Wang    2015   China   ESCC           87    44                    19   38   32   24   \_        43   17   13   17   10   \_   \_   GAPDH       median   Data in paper    2.371(1.284-6.115)
  Zhang   2018   China   GC             76    38                    13   \_   30   15   \_   25   38   18        24   6    \_   14   GAPDH       median   Data in paper    1.95(1.52-2.49)
  Liu     2018   China   GC             75    42                    17   33   29   34        31   33   19   15   13   20        12   GAPDH       4.5      Data in paper    2.28(1.109-4.689)
  Wei     2018   China   Glioma         65    34                                             11   31                            23   GAPDH       median   Data in paper    2.983(1.189-4.739)
  Lv      2018   China   CRC            65    44                    19   32   33   36   27        21   17   21   14   7    11        GAPDH       NM       NM               NM

CRC colorectal cancer, HCC hepatocellular carcinoma, GC gastric cancer, BC breast cancer, PC prostate cancer, BL bladder cancer, ESCC esophageal squamouscell carcinoma, LTS large tumor size, DI depth of invasion, PD poor differentiation, LNM lymph node metastasis, DM distant metastasis, HTS high tumor stage, NM not mentioned, HR hazard ratio, OS overall survival.
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